دورية أكاديمية
أعرض في EDS

MicroRNA Biomarkers of High-Grade Cervical Intraepithelial Neoplasia in Liquid Biopsy.

التفاصيل البيبلوغرافية
العنوان: MicroRNA Biomarkers of High-Grade Cervical Intraepithelial Neoplasia in Liquid Biopsy.
المؤلفون: Causin RL; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP 14784-400, Brazil., da Silva LS; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP 14784-400, Brazil., Evangelista AF; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP 14784-400, Brazil., Leal LF; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP 14784-400, Brazil., Souza KCB; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP 14784-400, Brazil., Pessôa-Pereira D; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP 14784-400, Brazil., Matsushita GM; Department of Pathology, Barretos Cancer Hospital, Barretos, SP 14784-400, Brazil., Reis RM; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP 14784-400, Brazil.; Life and Health Sciences Research Institute (ICVS), Medical School, University of Minho, Braga, Portugal. ICVS/3B's-PT Government Associate Laboratory, Braga, Guimarães, Portugal., Fregnani JHTG; A. C. Camargo Cancer Center, São Paulo, SP 01509-010, Brazil., Marques MMC; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP 14784-400, Brazil.; Barretos School of Health Sciences, Dr. Paulo Prata-FACISB, Barretos, SP 14785-002, Brazil.
المصدر: BioMed research international [Biomed Res Int] 2021 Apr 13; Vol. 2021, pp. 6650966. Date of Electronic Publication: 2021 Apr 13 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York, NY : Hindawi Pub. Co.
مواضيع طبية MeSH: Biomarkers, Tumor/*genetics , Cervix Uteri/*pathology , MicroRNAs/*genetics , Uterine Cervical Neoplasms/*genetics , Uterine Cervical Neoplasms/*pathology , Uterine Cervical Dysplasia/*genetics , Uterine Cervical Dysplasia/*pathology, Adult ; Aged ; Area Under Curve ; Biomarkers, Tumor/metabolism ; Computer Simulation ; Down-Regulation/genetics ; Female ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Humans ; Liquid Biopsy ; Logistic Models ; MicroRNAs/metabolism ; Middle Aged ; Neoplasm Grading ; Papillomavirus Infections/complications ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Risk Factors ; Up-Regulation/genetics ; Uterine Cervical Neoplasms/virology ; Young Adult ; Uterine Cervical Dysplasia/virology
مستخلص: New prevention strategies are needed to detect cervical intraepithelial neoplasia (CIN). The microRNA expression analysis has already been reported as molecular biomarkers in the early detection of cervical cancer (CC) through minimally invasive samples, such as liquid biopsy, obtained through collection using liquid-based cytology (LBC). In this study, we aimed to identify molecular signatures of microRNAs in cervical precursor lesions from LBC cervical and the molecular pathways potentially associated with the CC progression. We analyzed 31 LBC cervical samples from women who underwent colposcopy. These samples were divided into two groups: the first group was composed of samples without precursor lesions of CC, considering the control group, referred to as healthy female subjects (HFS; n = 11). The second group corresponded to women diagnosed with cervical interepithelial neoplasia grade 3 (CIN 3; n = 20). We performed microRNA and gene expression profiling using the nCounter® miRNA Expression Assays (NanoString Technology) and PanCancer Pathways (NanoString Technology), respectively. A microRNA target prediction was performed by mirDIP, and molecular pathway interaction was constructed using Cytoscape. Bidirectional in silico analyses and Pearson's correlation were performed for associated the relation between genes, and miRNAs differentially expressed related cervical cancer progression were performed. We found that the expression of nine microRNAs was significantly higher, two were downregulated (miR-381-3p and miR-4531), and seven miRNAs were upregulated (miR-205-5p, miR-130a-3p, miR-3136-3p, miR-128-2-5p, let-7f-5p, miR-202-3p, and miR-323a-5p) in CIN 3 (fold change ≥ 2 and p ≤ 0.05). The miRNA expression patterns were independent of hr-HPV infection. We identified four miRNAs (miR-205-5p, miR-130a-3p, miR-4531, and miR-381-3p) that could be used as biomarkers for CIN 3 in LBC samples through multiple logistic regression analyses. We found 16 genes differentially expressed between CIN 3 and HSF samples (fold change ≥ 2 and p ≤ 0.05). We found the correlation between miR-130a-3p and CCND1( R = -0.52; p = 0.0029), miR-205-5p and EGFR ( R = 0.53; p = 0.0021), and miR-4531 and SMAD2 ( R = -0.54; p = 0.0016). In addition, we demonstrated the most significant pathways of the targets associated with cervical cancer progression (FDR-corrected p < 0.001). This study demonstrated that miRNA biomarkers may distinguish healthy cervix and CIN 3 and regulate important molecular pathways of carcinogenesis.
Competing Interests: The authors declare that there is no conflict of interest regarding the publication of this paper.
(Copyright © 2021 Rhafaela L. Causin et al.)
References: J Cell Biochem. 2019 Jan;120(1):778-789. (PMID: 30161290)
BMC Cancer. 2018 Jun 27;18(1):696. (PMID: 29945565)
Mol Cancer. 2017 Apr 14;16(1):80. (PMID: 28410618)
QJM. 2017 Jan;110(1):11-15. (PMID: 27345415)
Int J Oncol. 2018 Oct;53(4):1395-1434. (PMID: 30085333)
Oncol Lett. 2017 May;13(5):3586-3598. (PMID: 28529583)
Nat Rev Genet. 2011 Nov 18;12(12):861-74. (PMID: 22094949)
Lancet. 2013 Sep 7;382(9895):889-99. (PMID: 23618600)
Mutat Res. 2011 Dec 1;717(1-2):1-8. (PMID: 21458467)
J Cell Physiol. 2019 Aug;234(10):17064-17099. (PMID: 30891784)
Nat Rev Cancer. 2015 Jun;15(6):321-33. (PMID: 25998712)
J Cancer. 2017 Aug 22;8(14):2699-2703. (PMID: 28928858)
Med Sci Monit. 2018 Sep 12;24:6387-6397. (PMID: 30207328)
Nat Rev Genet. 2019 Feb;20(2):71-88. (PMID: 30410101)
Int J Mol Sci. 2018 Feb 07;19(2):. (PMID: 29414899)
Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6131-8. (PMID: 24753594)
Genome Res. 2003 Nov;13(11):2498-504. (PMID: 14597658)
Cancer Cell Int. 2017 Jun 9;17:63. (PMID: 28615991)
Int J Cancer. 2019 Apr 15;144(8):1941-1953. (PMID: 30350310)
Oncol Rep. 2019 Jun;41(6):3167-3178. (PMID: 30942460)
BJOG. 2016 Jan;123(1):59-66. (PMID: 26177672)
Biol Res. 2018 Oct 11;51(1):39. (PMID: 30309377)
Cell Physiol Biochem. 2017;44(5):1923-1938. (PMID: 29224008)
Int J Cancer. 2019 Jan 15;144(2):372-379. (PMID: 30192375)
Tumour Biol. 2017 Jun;39(6):1010428317701308. (PMID: 28651495)
Gynecol Oncol. 2018 Sep;150(3):545-551. (PMID: 29960712)
Curr Infect Dis Rep. 2019 Mar 19;21(4):13. (PMID: 30888517)
Int J Mol Sci. 2018 Aug 07;19(8):. (PMID: 30087246)
Int J Clin Exp Pathol. 2019 May 01;12(5):1518-1528. (PMID: 31933969)
Arch Gynecol Obstet. 2015 Oct;292(4):905-13. (PMID: 25851497)
Mol Med Rep. 2020 Jan;21(1):209-219. (PMID: 31746391)
Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188306. (PMID: 31398380)
Trends Mol Med. 2010 Sep;16(9):398-406. (PMID: 20667783)
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (MicroRNAs)
0 (RNA, Messenger)
تواريخ الأحداث: Date Created: 20210506 Date Completed: 20210525 Latest Revision: 20221207
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8060087
DOI: 10.1155/2021/6650966
PMID: 33954190
قاعدة البيانات: MEDLINE
الوصف
تدمد:2314-6141
DOI:10.1155/2021/6650966